01575nam 2200433 450 991071498180332120221102200834.0(CKB)4100000011919708(NjHacI)994100000011919708(OCoLC)855729913(EXLCZ)99410000001191970820221102d2013 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierOral contraceptive use for the primary prevention of ovarian cancer /Laura J. Havrilesky [and thirteen others]Rockville, MD :Agency for Healthcare Research and Quality (US),[2013]©20131 online resource (514 pages) illustrationsEvidence reports/technology assessments ;Number 212"June 2013."Includes bibliographical references.Evidence report/technology assessment ;Number 212.Oral contraceptivesSide effectsOvariesCancerPreventionOral contraceptivesSide effects.OvariesCancerPrevention.613.9432Havrilesky Laura J.1353533United States.Agency for Healthcare Research and Quality,Duke University Evidence-based Practice Center.NjHacINjHaclBOOK9910714981803321Oral contraceptive use for the primary prevention of ovarian cancer3262525UNINA